News on haematological malignancies
A drug combination can safely prevent transplanted stem cells (graft) from attacking the recipient’s (host)…
Mount Sinai physician-scientists in the USA have found that a novel therapy for the bone…
In a phase III trial, a combination of ivosidenib and azacitidine was found superior in…
A study of nearly 25,000 young people with ALL reveals significant gaps in survival rates…
Patients receiving the anti-CD38 monoclonal antibody isatuximab in addition to the standard three- component induction…
An interim analysis of the TRANSFORM trial comparing CAR T-cell therapy lisocabtagene maraleucel (liso-cel) to…
The Phase II ZUMA-12 trial expands on the ZUMA-1 findings by evaluating the use of axicabtagene ciloleucel…
Follow-up data from the Phase II ZUMA-5 trial showed a long-term survival benefit with axicabtagene ciloleucel (axi-cel)…
A phase I/II trial for the experimental drug mosunetuzumab met its primary endpoint, leading to…
A combination of five existing drugs keeps cancer at bay for longer in patients with…